| abstract |
The present invention relates to a composition for inducing direct transdifferentiation into oligodendrocyte progenitor cells (OPCs) from somatic cells, the composition containing at least one protein selected from the group consisting of direct transdifferentiation factors OCT4, SOX1, SOX2, SOX10, OLIG2, NKX2.2, and NKX6.2 , a nucleic acid molecule coding the protein, or a vector including the nucleic acid molecule introduced thereinto; a pharmaceutical composition for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for treating spinal cord injuries or demyelination diseases; a composition for screening drugs for the treatment of spinal cord injuries or demyelination diseases; a 3D printing biomaterial composition for manufacturing artificial tissues for the treatment of spinal cord injuries or demyelination diseases; and a method for direct transdifferentiation into oligodendrocyte progenitor cells from somatic cells. According to the present invention, the oligodendrocyte progenitor cells are prepared from somatic cells through direct transdifferentiation, and thus can be favorably utilized for the treatment of spinal cord injuries and demyelination diseases. |